Grimes & Company Has Cut Michael Kors Holdings LTD (KORS) Holding By $3.15 Million; Profile of 4 Analysts Covering Immune Pharmaceuticals Inc. (IMNP)

April 24, 2018 - By Richard Conner

Michael Kors Holdings Limited (NYSE:KORS) Logo

Grimes & Company Inc decreased Michael Kors Holdings Ltd. (KORS) stake by 44.69% reported in 2017Q4 SEC filing. Grimes & Company Inc sold 50,778 shares as Michael Kors Holdings Ltd. (KORS)’s stock declined 2.98%. The Grimes & Company Inc holds 62,857 shares with $3.96 million value, down from 113,635 last quarter. Michael Kors Holdings Ltd. now has $10.33B valuation. The stock increased 4.37% or $2.84 during the last trading session, reaching $67.85. About 2.82 million shares traded or 26.89% up from the average. Michael Kors Holdings Limited (NYSE:KORS) has risen 62.72% since April 24, 2017 and is uptrending. It has outperformed by 51.17% the S&P500.

Among 4 analysts covering Immune Pharma (NASDAQ:IMNP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immune Pharma had 4 analyst reports since October 8, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, October 13 by Chardan Capital Markets. TH Capital initiated the shares of IMNP in report on Thursday, October 8 with “Buy” rating. The firm has “Buy” rating given on Thursday, October 8 by Roth Capital. See Immune Pharmaceuticals Inc. (NASDAQ:IMNP) latest ratings:

05/01/2018 Broker: Maxim Group Rating: Buy New Target: $3.0

The stock increased 1.00% or $0.0034 during the last trading session, reaching $0.3444. About 180,087 shares traded. Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has declined 87.86% since April 24, 2017 and is downtrending. It has underperformed by 99.41% the S&P500.

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company has market cap of $10.99 million. The companyÂ’s lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohnÂ’s, and ulcerative colitis diseases. It currently has negative earnings. It also develops NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, which is in preclinical stage for the treatment of atopic dermatitis and psoriasis.

Since February 13, 2018, it had 0 insider purchases, and 6 insider sales for $44.48 million activity. Reitman Stephen F sold 6,500 shares worth $406,065. IDOL JOHN D had sold 150,000 shares worth $9.34 million. Kors Michael David sold $15.12 million worth of stock. On Friday, February 16 the insider Benedetto M William sold $255,752.

Grimes & Company Inc increased Pfizer Inc (NYSE:PFE) stake by 9,143 shares to 67,101 valued at $2.43 million in 2017Q4. It also upped Ishares Msci Eafe (EFA) stake by 32,420 shares and now owns 215,677 shares. Spdr Doubleline Total Return was raised too.

Investors sentiment increased to 1.44 in 2017 Q4. Its up 0.50, from 0.94 in 2017Q3. It is positive, as 36 investors sold KORS shares while 112 reduced holdings. 103 funds opened positions while 110 raised stakes. 120.12 million shares or 5.14% less from 126.63 million shares in 2017Q3 were reported. Meag Munich Ergo Kapitalanlagegesellschaft Mbh has 0.1% invested in Michael Kors Holdings Limited (NYSE:KORS) for 38,709 shares. Nelson Van Denburg And Campbell Wealth Mngmt Group Inc Limited Liability Corp reported 350 shares. Courage Capital Mngmt Ltd Liability Company invested 2.26% in Michael Kors Holdings Limited (NYSE:KORS). Caprock Grp Incorporated reported 3,352 shares stake. American Intl Gp holds 0.01% of its portfolio in Michael Kors Holdings Limited (NYSE:KORS) for 54,224 shares. Dupont Cap Mgmt invested 0.18% in Michael Kors Holdings Limited (NYSE:KORS). 15.67 million are held by Vanguard Grp. Virtus Investment Advisers invested in 0.02% or 7,905 shares. Arrowstreet Partnership accumulated 1.02 million shares. Advisory Inc reported 0.01% of its portfolio in Michael Kors Holdings Limited (NYSE:KORS). Prelude Cap Ltd Liability reported 0.04% in Michael Kors Holdings Limited (NYSE:KORS). The New York-based Amalgamated Savings Bank has invested 0.05% in Michael Kors Holdings Limited (NYSE:KORS). Suntrust Banks, Georgia-based fund reported 4,711 shares. Panagora Asset invested 0.16% of its portfolio in Michael Kors Holdings Limited (NYSE:KORS). Moreover, Amundi Pioneer Asset has 0.02% invested in Michael Kors Holdings Limited (NYSE:KORS).

Analysts await Michael Kors Holdings Limited (NYSE:KORS) to report earnings on May, 30. They expect $0.58 EPS, down 20.55% or $0.15 from last year’s $0.73 per share. KORS’s profit will be $88.26M for 29.25 P/E if the $0.58 EPS becomes a reality. After $1.77 actual EPS reported by Michael Kors Holdings Limited for the previous quarter, Wall Street now forecasts -67.23% negative EPS growth.

Michael Kors Holdings Limited (NYSE:KORS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: